HC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a note issued to investors on Thursday, Benzinga reports. They currently have a $21.00 price target on the stock. HC Wainwright's target price indicates a potential upside of 448.30% from the company's previous close.

PDSB has been the subject of a number of other research reports. B. Riley restated a "buy" rating and set a $11.00 price objective (down previously from $14.00) on shares of PDS Biotechnology in a research note on Thursday, March 28th. StockNews.com lowered PDS Biotechnology from a "hold" rating to a "sell" rating in a research report on Saturday, March 16th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of PDS Biotechnology in a research report on Thursday. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, PDS Biotechnology presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

PDS Biotechnology Stock Down 4.7 %

Shares of NASDAQ:PDSB traded down $0.19 during mid-day trading on Thursday, hitting $3.83. 1,065,301 shares of the company traded hands, compared to its average volume of 851,638. The firm has a market cap of $140.48 million, a P/E ratio of -2.78 and a beta of 1.75. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.33 and a current ratio of 4.33. PDS Biotechnology has a 52-week low of $2.59 and a 52-week high of $10.27. The firm's 50 day simple moving average is $4.09 and its 200 day simple moving average is $4.78.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last issued its quarterly earnings data on Wednesday, March 27th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.05. On average, equities analysts anticipate that PDS Biotechnology will post -1.55 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PDSB. Inspirion Wealth Advisors LLC raised its stake in PDS Biotechnology by 5.5% during the 1st quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company's stock valued at $1,406,000 after acquiring an additional 18,383 shares in the last quarter. Commonwealth Equity Services LLC raised its stake in PDS Biotechnology by 4.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 66,578 shares of the company's stock valued at $336,000 after acquiring an additional 3,025 shares in the last quarter. Raymond James & Associates bought a new stake in PDS Biotechnology during the 3rd quarter valued at $123,000. Corton Capital Inc. bought a new stake in PDS Biotechnology during the 3rd quarter valued at $112,000. Finally, WINTON GROUP Ltd raised its stake in PDS Biotechnology by 24.8% during the 3rd quarter. WINTON GROUP Ltd now owns 21,256 shares of the company's stock valued at $107,000 after acquiring an additional 4,221 shares in the last quarter. Institutional investors and hedge funds own 26.84% of the company's stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.